Axitinib
Back to searchMolecule Structure
Scientific Name
Axitinib
Description of the Drug
Axitinib is an oral VEGFR and kinase inhibitor used for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB06626
http://www.drugbank.ca/drugs/DB06626
Brand Name(s)
Inlyta
Company Owner(s)
Pf Prism Cv
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Vascular endothelial growth factor receptor | PROTEIN FAMILY | INHIBITOR | CHEMBL2095227 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL172918 | ||
| DrugBank | DB06626 | ||
| PubChem: Thomson Pharma | 14804960 | ||
| PubChem | 6450551 | ||
| LINCS | LSM-43191 | ||
| Nikkaji | J2.302.956A | ||
| PDBe | AXI | ||
| BindingDB | 25117 | ||
| EPA CompTox Dashboard | DTXSID3049049 | ||
| DrugCentral | 4225 | ||
| Brenda | 14173 | 66997 | 213518 |
| ChemicalBook | CB81011728 | ||
| Guide to Pharmacology | 5659 | ||
| rxnorm | INLYTA | AXITINIB | |
| PubChem: Drugs of the Future | 26683791 | ||
| ChEBI | 66910 | ||
| ZINC | ZINC000003816287 |
